Ost P - Search Results

1

Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E²-RADIatE OligoCare study.

Christ SM, Alongi F, Ricardi U, Scorsetti M, Livi L, Balermpas P, Lievens Y, Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Widder J, Peulen H, Dirix P, Bral S, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier B, Ivaldi GB, Clementel E, Fortpied C, Oppong FB, Ost P, Guckenberger M. Christ SM, et al. Among authors: ost p. Radiother Oncol. 2024 Jun;195:110235. doi: 10.1016/j.radonc.2024.110235. Epub 2024 Mar 19. Radiother Oncol. 2024. PMID: 38508239 Free article.

2

Early biomarkers related to secondary primary cancer risk in radiotherapy treated prostate cancer patients: IMRT versus IMAT.

Werbrouck J, Ost P, Fonteyne V, De Meerleer G, De Neve W, Bogaert E, Beels L, Bacher K, Vral A, Thierens H. Werbrouck J, et al. Among authors: ost p. Radiother Oncol. 2013 Jun;107(3):377-81. doi: 10.1016/j.radonc.2013.05.014. Epub 2013 Jun 19. Radiother Oncol. 2013. PMID: 23791364 Free article.

3

Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: toxicity and matched case comparison with postoperative prostate bed-only radiotherapy.

Van Praet C, Ost P, Lumen N, De Meerleer G, Vandecasteele K, Villeirs G, Decaestecker K, Fonteyne V. Van Praet C, et al. Among authors: ost p. Radiother Oncol. 2013 Nov;109(2):222-8. doi: 10.1016/j.radonc.2013.08.021. Epub 2013 Sep 7. Radiother Oncol. 2013. PMID: 24016674

4

Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome.

Fonteyne V, Lumen N, Ost P, Van Praet C, Vandecasteele K, De Gersem Ir W, Villeirs G, De Neve W, Decaestecker K, De Meerleer G. Fonteyne V, et al. Among authors: ost p. Radiother Oncol. 2013 Nov;109(2):229-34. doi: 10.1016/j.radonc.2013.08.006. Epub 2013 Sep 7. Radiother Oncol. 2013. PMID: 24016677

5

Integrated models for the prediction of late genitourinary complaints after high-dose intensity modulated radiotherapy for prostate cancer: making informed decisions.

De Langhe S, De Meerleer G, De Ruyck K, Ost P, Fonteyne V, De Neve W, Thierens H. De Langhe S, et al. Among authors: ost p. Radiother Oncol. 2014 Jul;112(1):95-9. doi: 10.1016/j.radonc.2014.04.005. Epub 2014 Jun 17. Radiother Oncol. 2014. PMID: 24951017

6

Rectal toxicity after intensity modulated radiotherapy for prostate cancer: which rectal dose volume constraints should we use?

Fonteyne V, Ost P, Vanpachtenbeke F, Colman R, Sadeghi S, Villeirs G, Decaestecker K, De Meerleer G. Fonteyne V, et al. Among authors: ost p. Radiother Oncol. 2014 Dec;113(3):398-403. doi: 10.1016/j.radonc.2014.10.014. Epub 2014 Nov 28. Radiother Oncol. 2014. PMID: 25441610

7

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.

Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, Henderson D, Casamassima F, Orecchia R, Surgo A, Brown L, Tree A, Miralbell R, De Meerleer G. Ost P, et al. Eur Urol. 2016 Jan;69(1):9-12. doi: 10.1016/j.eururo.2015.07.004. Epub 2015 Jul 16. Eur Urol. 2016. PMID: 26189689

8

Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity.

Sundahl N, De Meerleer G, Villeirs G, Ost P, De Neve W, Lumen N, De Visschere P, Van Eijkeren M, Fonteyne V. Sundahl N, et al. Among authors: ost p. Radiother Oncol. 2016 Jun;119(3):398-404. doi: 10.1016/j.radonc.2016.04.031. Epub 2016 May 6. Radiother Oncol. 2016. PMID: 27162160

9

Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial.

Fonteyne V, Dirix P, Junius S, Rammant E, Ost P, De Meerleer G, Swimberghe M, Decaestecker K. Fonteyne V, et al. Among authors: ost p. BMC Cancer. 2017 May 2;17(1):308. doi: 10.1186/s12885-017-3302-9. BMC Cancer. 2017. PMID: 28464906 Free PMC article. Clinical Trial.

10

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.

Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, Deroose CM, Goffin K, Herrmann K, Hoekstra OS, Kramer G, Lievens Y, Lopci E, Pasquier D, Petersen LJ, Talbot JN, Zacho H, Tombal B, deSouza NM. Lecouvet FE, et al. Among authors: ost p. Lancet Oncol. 2018 Oct;19(10):e534-e545. doi: 10.1016/S1470-2045(18)30571-0. Epub 2018 Oct 1. Lancet Oncol. 2018. PMID: 30303127 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

303 results

Search Page